Codexis +84% AH on Glaxo licensing pact


Codexis (NASDAQ:CDXS) +84.4% AH on news it granted a license to GlaxoSmithKline (NYSE:GSK) to use its CodeEvolver platform technology to develop enzymes for use in pharmaceutical and health care products.

CDXS says it is eligible to receive up to $25M over a period of about two years, and could receive additional milestone payments of up to $38.5M per project, depending on successful application of the technology.

From other sites
Comments (2)
  • maven pharm
    , contributor
    Comments (257) | Send Message
     
    Glaxo is a winning stock. Firstly although they sold their oncology business to Novartis and bought out another firms vaccines business; the research know how is still there. The stock has the added possibility of being bought out by an American pharmaceutical company due to its English ownership. The asthmatic business is second to none and the dividend is solid. I see Glaxo trading in the low 70's in several years. This stock is a great long term holding.
    14 Jul 2014, 11:39 PM Reply Like
  • Michael Clark
    , contributor
    Comments (11583) | Send Message
     
    What about Codexis?
    15 Jul 2014, 01:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs